Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review.

ABSTRACT:

Objective

Update the last known review, and summarize the definitions, diagnostic criteria, reported risk factors, possible mechanisms and potential biomarkers of hyperprogressive disease (HPD) under immunotherapy.

Background

Immunotherapy is a relatively new systemic therapy adding a new method of treatment of especially advanced cancer patients. In a variety of immunotherapies, however, an unexpected acceleration of tumor growth, known as HPD, is observed in approximately 30% of patients after immune checkpoint inhibitor (ICI) treatment. HPD has a deleterious survival effect on patients and represents an urgent issue for both clinicians and patients. Existing literature has reviewed and summarized the definition, diagnostic criteria, reported risk factors and possible mech

SUBMITTER: Lin M 

PROVIDER: S-EPMC8350090 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature